Predicting novel drug candidates against Covid-19 using generative deep neural networks
Related Experiment Video
Updated: Oct 15, 2025

DNA Virus Detection System Based on RPA-CRISPR/Cas12a-SPM and Deep Learning
Published on: May 10, 2024
Santhosh Amilpur1, Raju Bhukya1
1National Institute of Technology, Waranagl, 506004, India.
Abstract:
The novel Coronavirus outbreak has created a massive economic crisis, and many succumb to death, disturbing the lives of mankind all over the world. Currently, there are no viable treatment for this condition, drug development approaches are being pursued with vigor. The major treatment options are to repurpose existing drugs or to find new ones. Traditional methods for drug discovery take a longer time, so there is an urgent need to develop some alternative techniques that reduces search space for drug candidates. Towards this endeavor, we propose a novel drug discovery method that leverages on long short term memory (LSTM) model to generate novel molecules that are adept at binding with novel Coronavirus protease. Our study demonstrates that the proposed method is able to recreate novel molecules that correlate very much with the properties of trained molecules. Further, we fine-tune the model to generate novel drug-like molecules that are active towards a specific target. We consider 3CLPro, the main protease of novel Coronavirus, as a therapeutic target and demonstrated in silico screening to assess target structural binding affinities with docking simulations. We observed that 80% of generated molecules show docking free energy of less than -5.8 kcal/mol. The top generated drug candidate has the highest binding affinity with a docking score of -8.5 kcal/mol, which is very much lower when compared to approved existing commercial drugs including, Remdesivir. The low binding energy indicates that the generated molecules could be explored as potential drug candidates for Covid-19.
Insights
This study introduces a novel drug discovery method using a long short-term memory (LSTM) model to generate potential COVID-19 treatments. The AI-designed molecules show high binding affinity to the novel Coronavirus protease, offering promising therapeutic candidates.
Area of Science:
- Computational chemistry
- Artificial intelligence in drug discovery
- Virology
Background:
- The COVID-19 pandemic necessitates rapid development of effective treatments.
- Traditional drug discovery is time-consuming, highlighting the need for accelerated methods.
- Targeting the novel Coronavirus 3CL protease is a key strategy for therapeutic intervention.
Purpose of the Study:
- To develop an AI-driven approach for generating novel drug candidates against the novel Coronavirus.
- To identify molecules with high binding affinity to the 3CL protease using a long short-term memory (LSTM) model.
- To assess the potential of generated molecules as therapeutic agents for COVID-19.
Main Methods:
- Utilized a long short-term memory (LSTM) deep learning model for de novo molecule generation.
- Employed in silico screening and molecular docking simulations to evaluate binding affinities.
- Focused on the 3CL protease (3CLPro) as the primary therapeutic target.
Main Results:
- The LSTM model successfully generated novel molecules with properties similar to trained datasets.
- 80% of generated molecules exhibited a docking free energy below -5.8 kcal/mol.
- The top candidate molecule demonstrated a superior binding affinity (-8.5 kcal/mol) compared to Remdesivir.
Conclusions:
- The proposed AI method effectively generates promising drug candidates for COVID-19.
- Generated molecules show significant potential for targeting the novel Coronavirus 3CL protease.
- This approach offers a faster alternative for discovering novel antiviral therapeutics.
Related Concept Videos
Drug Discovery: Overview
Single Nucleotide Polymorphisms-SNPs